AbbVie Sees Continued Positive Results for Leukemia Treatment
11 June 2021 - 9:32PM
Dow Jones News
By Chris Wack
AbbVie said it saw continued positive results from a four-year
follow-up analysis of its Phase 3 CLL14 trial.
The pharmaceutical company said the trial showed that previously
untreated patients with chronic lymphocytic leukemia with
coexisting conditions who were treated with Venclyxto/Venclexta
venetoclax plus obinutuzumab continued to show longer
progression-free survival and higher rates of undetectable minimal
residual disease compared to patients receiving a standard of care
chemoimmunotherapy regimen of obinutuzumab and chlorambucil.
"The CLL14 trial results observed after four years of follow-up
with treatment of venetoclax plus obinutuzumab show that these
patients can experience long-lasting responses without disease
progression, years after stopping treatment," said Mohamed Zaki,
vice president and head of global oncology development at
AbbVie.
After a median follow-up of more than four years, patients
treated with the Venclyxto/Venclexta and obinutuzumab combination
continued to demonstrate longer progression free survival compared
to patients on treatment with obinutuzumab and chlorambucil, and
the risk of disease progression or death was reduced by 67%.
No new safety signals were observed in the four-year follow-up
analysis. The most frequently occurring serious adverse reactions
in patients receiving venetoclax in combination with obinutuzumab
were pneumonia, sepsis, febrile neutropenia, and TLS.
Venclyxto/Venclexta is being developed by AbbVie and Roche. It
is jointly commercialized by AbbVie and Genentech, a member of the
Roche Group, in the U.S. and by AbbVie outside of the U.S.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 11, 2021 07:20 ET (11:20 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Apr 2024 to May 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From May 2023 to May 2024